◇ Pillar Guide
The Complete Guide to GLP-1 Weight-Loss Drugs
Contents · 13 sections
Start by problem (most people start here)What this guide coversStart here: what GLP-1s are and how they workThe compounds, comparedUsing them well: food, side effects, and protecting your muscleResults and the long gameBeyond weight: the secondary benefitsAccess, cost and safetyCommon questions, answered in depthThe bottom lineFrequently asked questionsKey referencesThe compounds, in depthWhat this guide covers
The complete guide to GLP-1 weight-loss medications
TL;DR
- Four famous brands, two approved molecules - Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are both tirzepatide.
- The headline trial figures - semaglutide −14.9% at 68 weeks, tirzepatide up to −22.5% at 72 weeks, CagriSema −20.4% at 68 weeks, and investigational retatrutide up to −28% at 80 weeks.
- Those numbers come from different trials and can't be ranked directly - only tirzepatide versus semaglutide is a true head-to-head.
- The benefits reach past the scale - SELECT cut major cardiovascular events by 20%, and semaglutide took an accelerated MASH approval in 2025.
- Plateaus are a new metabolic equilibrium, not receptor burnout - and stopping brings roughly two-thirds of the weight back within a year for semaglutide, preferentially as fat.
- Prescription-only across Malaysia, Indonesia, Thailand and Singapore - the grey market carries documented mislabelling, contamination and counterfeit risk.
Educational content, not medical advice. This is an overview that links to detailed guides on each topic; compound and trial data lead, investigational agents are labelled, and no doses appear as instructions. All weight-loss medications are prescription-only and physician-supervised.
GLP-1 medications have, in a few short years, become the most effective weight treatments medicine has ever had - and also the most misunderstood, over-hyped and grey-marketed. This guide is the honest map: what these drugs actually are, how they work, how the options compare, what to expect month by month, the side effects and how to manage them, what happens when you stop, and how to access them safely across Southeast Asia. Each section summarises a topic and links to a full deep-dive. Start anywhere - or read straight through.
GLP-1s are one class within the broader Complete Guide to Peptides.
Start by problem (most people start here)
- How to lose weight - the honest, evidence-based version
- How to lose fat without losing muscle · GLP-1 muscle loss
- "Ozempic face" & hair loss · Hitting a plateau
- Do you need a doctor for GLP-1s? · Side effects timeline
What this guide covers
Start here
- GLP-1 beginner's guide: your first months
- How GLP-1 agonists actually work
- Mounjaro vs Wegovy vs Ozempic: the honest comparison
The compounds, compared
- Tirzepatide vs semaglutide vs retatrutide vs CagriSema
- When will CagriSema be approved?
- Cagrilintide as a GLP-1 bridge or stack
- Cagrilintide as a bridge or stack, in plain English - the amylin pathway explained from scratch, and whether cagrilintide lowers ghrelin
- Retatrutide and cagrilintide: do different mechanisms mean you can combine them? - why separate pathways make a pairing conceivable, not proven
- Tirzepatide vs retatrutide: what's next after Mounjaro
- Retatrutide: the evidence so far, and what's missing
- What the glucagon arm of retatrutide actually does - the third receptor, and why glucagon sits in a weight compound
- Retatrutide vs bariatric surgery - how the drug frontier compares to surgery
- Why people stop taking retatrutide - five distinguishable reasons, and why they don't share an answer
Using them well
- What to eat on a GLP-1
- Side effects: the timeline and red flags
- Losing fat, not muscle
- "Ozempic face" and hair loss, explained
- Loose skin after rapid weight loss - what recovers, what doesn't, and what actually has outcome data
- The drug is not the protocol: resistance training & protein
Dose questions, answered without a dose
- Why GLP-1 doses start low - the physiology behind slow escalation
- Is there a "sweet spot" dose? - what dose–response actually looks like, and why an average can't locate you on it
- Is there a retatrutide dosing guide? - why no approved retatrutide dose exists
Results and the long game
- Why weight loss stalls (the plateau)
- The "resensitizing" myth vs metabolic reality
- Keeping the weight off after you stop
- Three years of tirzepatide evidence - what SURMOUNT-1 at 176 weeks does and doesn't show
Beyond weight
- GLP-1s and sleep apnea (first drug for OSA)
- GLP-1s and your joints
- Retatrutide and knee pain: what TRIUMPH-4 showed - the ~75.8% number and the confound behind it
- Retatrutide and cardiovascular disease: reading TRIUMPH-3
- GLP-1s and the brain: neuroprotection evidence
- Are GLP-1s anti-aging drugs? The longevity evidence - from the Biological Age guide: what the 2026 claims rest on, and why no ageing trial has been run
- GLP-1s and alcohol use disorder: what the 2026 trial found - studied, not approved
- GLP-1s and bone density
- GLP-1s and cancer risk, both ways
- GLP-1s and gallbladder risk - the drug, the rapid weight loss, and which one carries the risk
- GLP-1s and the liver: the MASH approval - what the 2025 semaglutide MASH approval actually covers
Access, cost and safety
- Do you need a doctor? (Southeast Asia)
- What weight-loss injections cost in KL
- Retatrutide expanded access, explained
- Which side effects mean you should call your prescriber - the symptoms that need assessment rather than patience
- Vision changes on a GLP-1 - which eyesight changes settle, and which need urgent assessment
Common questions
- How long until a GLP-1 works?
- Microdosing GLP-1s: does it work?
- Oral vs injectable GLP-1s
- Foundayo (orforglipron): should you switch from injections?
- Aleniglipron: what a Phase 2 oral GLP-1 result does and doesn't establish - pipeline, not an option
- GLP-1s and alcohol & interactions
- What not to mix with a GLP-1: the interactions worth knowing
- Does GLP-1 injection site matter? What the absorption data shows
- Retatrutide side effects, read honestly
- GLP-1s for women: PCOS, fertility & hormones
- Do GLP-1 drugs work better for women than men? - what the 2026 meta-analysis found, and why a group average won't predict your result
- GLP-1 myths, debunked
Start here: what GLP-1s are and how they work
GLP-1 receptor agonists copy a hormone your gut releases after eating. They slow stomach emptying, act on the brain's appetite centres so you feel full and think about food less, and steady blood sugar. Semaglutide works on one pathway (GLP-1); tirzepatide adds a second (GIP) for more effect. The famous brand names hide just two molecules: Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are both tirzepatide.
If you're new to all this, the beginner's guide walks through your first months end to end; how GLP-1 agonists work explains the mechanism in plain language; and Mounjaro vs Wegovy vs Ozempic untangles the names. Read the full guides at the links.
The compounds, compared
There are essentially four compounds driving the whole conversation, ranked by how many hormone pathways each hits:
| Semaglutide (Wegovy/Ozempic) | Tirzepatide (Mounjaro/Zepbound) | CagriSema (cagrilintide + semaglutide) | Retatrutide | |
|---|---|---|---|---|
| Pathways | GLP-1 | GLP-1 + GIP | Amylin + GLP-1 | GLP-1 + GIP + glucagon |
| Mean weight loss | −14.9% (68 wk) | up to −22.5% (72 wk) | −20.4% (68 wk) | up to −28% (80 wk) |
| Status | Approved | Approved | Investigational | Investigational (Phase 3) |
| Note | Largest heart-outcomes dataset | Most potent approved option | Missed its ~25% target | Highest number; not yet available |
The crucial caveat: these numbers come from different trials and can't be ranked directly - only tirzepatide vs semaglutide is a true head-to-head. The four-way comparison lays this out in full; cagrilintide covers the amylin outlier; and tirzepatide vs retatrutide covers the investigational frontier. Read the full guides at the links.
A second axis is now moving. Every compound in the table above differs by how many receptors it engages. A separate line of development is changing how often the injection has to happen - with an investigational monthly agent reporting Phase 2b data in 2026. These are independent axes, and conflating them produces the common error of treating "newest" as a single ranking. See ultra-long-acting monthly GLP-1s for what dosing interval does and does not change.
Using them well: food, side effects, and protecting your muscle
The drug controls appetite; you control the quality of the result. Two things decide whether the experience is smooth and the weight you lose is fat: what you eat and how the dose is titrated.
Side effects are mostly gastrointestinal, usually mild-to-moderate, and follow a predictable rhythm - they peak 2–3 weeks after each dose increase, then fade. Simple habits (protein-first meals, small simple food during titration, hydrating away from meals, skipping fizzy drinks) blunt most of them, while a minority are red flags that mean call your doctor. And because rapid loss strips some muscle, protein and resistance training are essential to losing fat rather than lean tissue.
The deep dives: what to eat on a GLP-1, the side-effect timeline and red flags, losing fat not muscle, and "Ozempic face" and hair loss - which explains why both are rapid-weight-loss effects, not drug toxicity. Read the full guides at the links.
Results and the long game
Two honest truths shape expectations. First, plateaus are normal - they're a new metabolic equilibrium, not the drug failing or your receptors "burning out," and the popular "resensitizing drug holiday" is largely a myth. Second, stopping tends to bring the weight back - about two-thirds within a year for semaglutide - preferentially as fat, which is why a maintenance or supervised-taper plan matters from the start.
Read more: why weight loss stalls, the resensitizing myth examined, and keeping the weight off. For the longest horizon anyone has actually published, three years of tirzepatide evidence reads SURMOUNT-1 at 176 weeks for what it covers and where it runs out. Read the full guides at the links.
Beyond weight: the secondary benefits
GLP-1s do more than move the scale. Semaglutide reduced major cardiovascular events by 20% in a large trial (SELECT), and in people with obesity and knee osteoarthritis it significantly cut knee pain - though that benefit is largely a consequence of the weight loss itself. The investigational triple agonist retatrutide echoed that pattern in TRIUMPH-4, cutting knee-OA pain up to ~75.8% alongside up to 28.7% weight loss - with the same weight-versus-drug confound to read carefully. See GLP-1s and your joints for the honest read. The organ-system picture cuts both ways: semaglutide received an accelerated approval in MASH in 2025, covered in GLP-1s and the liver, while pooled trial data shows a real signal for GLP-1s and gallbladder risk - much of it attributable to the rapid weight loss rather than the molecule. Read the full guides at the links.
Access, cost and safety
Across Southeast Asia - Malaysia, Indonesia, Thailand, Singapore - these are prescription-only medicines, approved and regulated, and available only through licensed clinics. The grey market (websites, social-media sellers, "research" vials) is the real hazard everywhere, with documented risks of mislabelled doses, contamination and counterfeits. And there's no single price: cost depends on the molecule, the dose you titrate to, and whether the quote includes the medical care that makes treatment safe.
Read more: do you need a doctor? (a country-by-country look across SEA) and what weight-loss injections cost in KL. Read the full guides at the links.
Common questions, answered in depth
Beyond the basics, a handful of questions come up again and again. How long until it works? Appetite shifts in days, real loss over months. Is microdosing legit? Mostly a trendy label over sound "lowest effective dose" practice. Pill or injection? Pills win on convenience, injectable tirzepatide on potency. Can you drink on it? Usually less, and it interacts with birth control. What about women, PCOS and fertility? Often helpful for PCOS, with real reproductive considerations. And the myths? Mostly moral judgements and half-truths. Read the full guides at the links.
The bottom line
GLP-1s are genuinely transformative - and genuinely medicine, not a lifestyle hack. Used well, with proper screening, slow titration, muscle protection, monitoring and a long-term plan, they're the most effective weight treatment available. Used carelessly - grey-market vials, no supervision, no plan for staying on or coming off - they're a fast way to lose muscle, feel terrible, and regain the weight as fat. The difference is the medicine around the molecule.
Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore semaglutide.
Frequently asked questions
What is a GLP-1? GLP-1 (glucagon-like peptide-1) is a gut hormone that signals fullness and steadies blood sugar after eating. "GLP-1 drugs" are engineered versions that copy it and last about a week, reducing appetite - the basis of medicines like Ozempic, Wegovy and (with a second pathway) Mounjaro.
Which GLP-1 is most effective for weight loss? By trial numbers, the investigational triple agonist retatrutide is highest (~28%), then tirzepatide (~22.5%), CagriSema (~20%) and semaglutide (~15%) - but those come from different trials and aren't directly comparable. Tirzepatide is the most potent approved and available option.
Are GLP-1s safe? They're well-studied prescription medicines with real benefits and manageable side effects when screened and monitored properly. They're not for everyone (e.g. certain thyroid-cancer and pancreatitis histories, or pregnancy), which is why a prescriber and monitoring matter.
Do you keep the weight off after stopping? Usually not without a plan - most weight returns within a year of stopping, preferentially as fat. Obesity behaves like a chronic condition, so maintenance or a supervised taper is the realistic model.
Can I buy GLP-1s without a doctor? In Malaysia, Indonesia, Thailand and Singapore they're prescription-only, and buying from unregulated online or social-media sellers is unsafe (and, in places like Singapore, illegal). Use a licensed clinic.
Educational content, not medical advice. GLP-1 and related medications are prescription-only and require physician screening, prescription and monitoring. Retatrutide and CagriSema are investigational and not approved; cross-trial comparisons are not head-to-head. Regulatory status differs by market and changes over time. Trial figures describe study populations; individual results vary. Claims for the Malaysian market are subject to MAB requirements.
Key references
- Wilding JPH, et al. STEP 1 (semaglutide). N Engl J Med. 2021;384:989–1002.
- Jastreboff AM, et al. SURMOUNT-1 (tirzepatide). N Engl J Med. 2022;387:205–216.
- Aronne LJ, et al. SURMOUNT-5 (tirzepatide vs semaglutide). N Engl J Med. 2025.
- Davies M, Garvey WT, et al. REDEFINE 1 (CagriSema). N Engl J Med. 2025. doi:10.1056/NEJMoa2502081.
- Eli Lilly. TRIUMPH-1 topline (retatrutide), 21 May 2026.
- Lincoff AM, et al. SELECT (semaglutide cardiovascular outcomes). N Engl J Med. 2023;389:2221–2232.
- Bliddal H, et al. STEP 9 (semaglutide, knee osteoarthritis). N Engl J Med. 2024;391(17):1573–1583.
The compounds, in depth
- Tirzepatide (Mounjaro/Zepbound): the honest guide - the most effective approved option
- What tirzepatide is actually doing to your body - a body-systems tour of the dual GIP/GLP-1 mechanism
- Semaglutide (Ozempic/Wegovy): the honest guide - the cornerstone, now in pill form
- Mounjaro vs Wegovy vs Ozempic - the brands compared
- Orforglipron (Foundayo): the GLP-1 pill with no food or water rules - the first small-molecule GLP-1 pill, and how it compares to semaglutide
Educational content only. This article is not a prescription, a dose, or a treatment recommendation. Products are sold for research use only - suitability, dosing and monitoring are not set on this site.